The agreement brings together Imugene’s oncolytic virus CF33-CD19 (onCARlytics) and JW’s CD19-directed autologous CAR-T therapy, Carteyva, in a program that spans preclinical studies through to a Phase 1 investigator-initiated clinical trial in China.
Imugene and JW Therapeutics join forces on first-in-class combination for solid tumours
November 27, 2025 Australian Biotech
Latest Video
New Stories
-
Medicines Australia tells productivity inquiry PBS rules leave out economic benefits
November 16, 2026 - -
First official US count confirms the broad uptake of GLP-1s for weight management
November 16, 2026 - - Latest News -
Can the PBS afford another agreement on the same terms?
November 16, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 13 November
November 13, 2026 - - Podcast -
A year on, Sanofi now asks staff to explain how they used AI
November 13, 2026 - - Latest News -
There is no need for AI to automate the care out of healthcare, Cohn warns
November 13, 2026 - -
Cochlear's global government affairs chief is putting AI to work
November 13, 2026 - - Latest News

